Literature DB >> 9054967

A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance.

G E Dale1, C Broger, A D'Arcy, P G Hartman, R DeHoogt, S Jolidon, I Kompis, A M Labhardt, H Langen, H Locher, M G Page, D Stüber, R L Then, B Wipf, C Oefner.   

Abstract

A single amino acid substitution, Phe98 to Tyr98, in dihydrofolate reductase (DHFR) is the molecular origin of trimethoprim (TMP) resistance in Staphylococcus aureus. This active site amino acid substitution was found in all S. aureus TMP-resistant clinical isolates tested. In order to explore the structural role of Tyr98 in TMP-resistance the ternary complexes of the chromosomal S. aureus DHFR (SaDHFR) with methotrexate (MTX) and TMP in the presence of nicotinamide adenine dinucleotide phosphate (NADPH) as well as that of mutant Phe98Tyr DHFR SaDHFR(F98Y) ternary folate-NADPH complex have been determined by X-ray crystallography. Critical evidence concerning the resistance mechanism has also been provided by NMR spectral analyses of 15N-labelled TMP in the ternary complexes of both wild-type and mutant enzyme. These studies show that the mutation results in loss of a hydrogen bond between the 4-amino group of TMP and the carbonyl oxygen of Leu5. This mechanism of resistance is predominant in both transferable plasmid-encoded and non-transferable chromosomally encoded resistance. Knowledge of the resistance mechanism at a molecular level could help in the design of antibacterials active against multi-resistant Staphylococcus aureus (MRSA), one of todays most serious problems in clinical infectology.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9054967     DOI: 10.1006/jmbi.1996.0770

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  54 in total

1.  Predicting resistance mutations using protein design algorithms.

Authors:  Kathleen M Frey; Ivelin Georgiev; Bruce R Donald; Amy C Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

Review 2.  Antibacterial Antifolates: From Development through Resistance to the Next Generation.

Authors:  Alexavier Estrada; Dennis L Wright; Amy C Anderson
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

3.  Characterization of dihydrofolate reductase genes from trimethoprim-susceptible and trimethoprim-resistant strains of Enterococcus faecalis.

Authors:  T M Coque; K V Singh; G M Weinstock; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  Protein design algorithms predict viable resistance to an experimental antifolate.

Authors:  Stephanie M Reeve; Pablo Gainza; Kathleen M Frey; Ivelin Georgiev; Bruce R Donald; Amy C Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-31       Impact factor: 11.205

5.  Structure-activity relationship for enantiomers of potent inhibitors of B. anthracis dihydrofolate reductase.

Authors:  Christina R Bourne; Nancy Wakeham; Baskar Nammalwar; Vladimir Tseitin; Philip C Bourne; Esther W Barrow; Shankari Mylvaganam; Kal Ramnarayan; Richard A Bunce; K Darrell Berlin; William W Barrow
Journal:  Biochim Biophys Acta       Date:  2012-09-20

6.  Structure-based design of guanosine analogue inhibitors targeting GTP cyclohydrolase IB towards a new class of antibiotics.

Authors:  George N Samaan; Naduni Paranagama; Ayesha Haque; David A Hecht; Manal A Swairjo; Byron W Purse
Journal:  Bioorg Med Chem Lett       Date:  2019-11-12       Impact factor: 2.823

7.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

8.  In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis.

Authors:  Esther W Barrow; Jürg Dreier; Stefan Reinelt; Philip C Bourne; William W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

9.  Identification of P218 as a potent inhibitor of Mycobacterium ulcerans DHFR.

Authors:  Gustavo P Riboldi; Rachael Zigweid; Peter J Myler; Stephen J Mayclin; Rafael M Couñago; Bart L Staker
Journal:  RSC Med Chem       Date:  2020-10-22

10.  High-level resistance to trimethoprim in clinical isolates of Campylobacter jejuni by acquisition of foreign genes (dfr1 and dfr9) expressing drug-insensitive dihydrofolate reductases.

Authors:  A Gibreel; O Sköld
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.